Published in CMAJ on August 17, 2004
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Reporting quality of social and psychological intervention trials: a systematic review of reporting guidelines and trial publications. PLoS One (2013) 1.05
Developing a reporting guideline for social and psychological intervention trials. Trials (2013) 0.96
A systematic review of the quality of reporting in published smoking cessation trials for pregnant women: an explanation for the evidence-practice gap? Implement Sci (2014) 0.85
The quality of reporting of RCTs used within a postoperative pain management meta-analysis, using the CONSORT statement. BMC Anesthesiol (2012) 0.82
Methodological Reporting Quality of Randomized Controlled Trials in 3 Leading Diabetes Journals From 2011 to 2013 Following CONSORT Statement: A System Review. Medicine (Baltimore) (2015) 0.82
Developing a reporting guideline for social and psychological intervention trials. Am J Public Health (2013) 0.82
A look at the potential association between PICOT framing of a research question and the quality of reporting of analgesia RCTs. BMC Anesthesiol (2013) 0.77
Developing a Reporting Guideline for Social and Psychological Intervention Trials. Res Soc Work Pract (2013) 0.77
Critical appraisal of reporting randomized clinical trials published in Iranian dental journals during 2003-2010. J Dent (Tehran) (2014) 0.75
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet (1999) 37.76
The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med (2001) 37.70
Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA (1996) 36.04
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet (2001) 31.74
CONSORT statement: extension to cluster randomised trials. BMJ (2004) 16.50
Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA (2001) 13.36
The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med (2003) 10.28
Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med (2003) 8.58
Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA (2001) 8.15
Value of flow diagrams in reports of randomized controlled trials. JAMA (2001) 7.06
How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess (2003) 4.62
The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials (2002) 3.62
Reporting of safety data from randomised trials. Lancet (1998) 1.35
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine (2002) 1.11
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA (2004) 23.87
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 22.34
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol (2009) 17.92
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
CONSORT statement: extension to cluster randomised trials. BMJ (2004) 16.50
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med (2010) 16.11
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med (2008) 13.87
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (2010) 12.98
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
Epidemiology and reporting characteristics of systematic reviews. PLoS Med (2007) 11.51
Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med (2004) 11.47
Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust (2006) 11.40
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ (2004) 10.75
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ (2008) 9.98
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med (2010) 9.30
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med (2006) 8.25
SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med (2013) 8.21
Comparison of registered and published primary outcomes in randomized controlled trials. JAMA (2009) 7.89
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One (2009) 7.60
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ (2014) 7.55
Consort 2010 statement: extension to cluster randomised trials. BMJ (2012) 7.47
Guidance for developers of health research reporting guidelines. PLoS Med (2010) 7.43
Diagnostic tests 4: likelihood ratios. BMJ (2004) 7.33
What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials (2006) 7.32
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med (2010) 6.88
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (2003) 6.61
Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet (2002) 6.61
Epidemiology and reporting of randomised trials published in PubMed journals. Lancet (2005) 6.55
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol (2013) 5.93
CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med (2008) 5.85
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (2010) 5.70
The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ (2010) 5.58
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat (2007) 5.52
An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ (2009) 5.45
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Bias and causal associations in observational research. Lancet (2002) 5.36
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ (2005) 5.36
The design of simulation studies in medical statistics. Stat Med (2006) 5.30
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
Ghost authorship in industry-initiated randomised trials. PLoS Med (2007) 4.95
Refining clinical diagnosis with likelihood ratios. Lancet (2005) 4.84
Quantification of the completeness of follow-up. Lancet (2002) 4.77
Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA (2012) 4.73
Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA (2010) 4.56
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Prognosis and prognostic research: what, why, and how? BMJ (2009) 4.46
An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ (2010) 4.46
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med (2009) 4.43
REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat (2006) 4.42
Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ (2009) 4.38
Prognosis and prognostic research: Developing a prognostic model. BMJ (2009) 4.38
Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev (2012) 4.36
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med (2015) 4.32
Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol (2002) 4.30
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials (2010) 4.28